Company intelligence / Profile preview

Aenitis Technologies

Paris, Ile-de-France, Franceaenitis.fr ↗

Ownership: Private
Development stage: Commercial

Overview

Proprietary technology demonstrated proof-of-concept for gentle, label-free manipulation of various cell types. Devices are being adopted in research and clinical manufacturing settings.

Therapeutic areas: Hematology
Modalities: Cell therapy (focus on cell and gene therapy manufacturing)
Industry: Non-Drug Biotech

Drug pipeline

1 asset

Mitis

Commercial

Indications: Cell processing, Cell sorting, Cell isolation, Cell concentration, Cell washing

Partnerships

Supported by European Commission/EIC Fund Board/EIB/Seventure Partners

Beyond the preview

Go deeper on Aenitis Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aenitis Technologies.

Explore the full profile